Cargando…

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use

IMPORTANCE: Despite prevalent polysubstance use, treatment patterns and outcomes for individuals with opioid use disorder (OUD) and cooccurring substance use disorders (SUD) are understudied. OBJECTIVE: To evaluate the distribution of buprenorphine and naltrexone initiation among individuals with OU...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Kevin Y., Mintz, Carrie M., Presnall, Ned, Bierut, Laura J., Grucza, Richard A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092203/ https://www.ncbi.nlm.nih.gov/pubmed/35536575 http://dx.doi.org/10.1001/jamanetworkopen.2022.11363

Ejemplares similares

Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder
por: Mintz, Carrie M., et al.
Publicado: (2022)

Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events
por: Xu, Kevin Y., et al.
Publicado: (2021)

Association Between Benzodiazepine Use With or Without Opioid Use and All-Cause Mortality in the United States, 1999-2015
por: Xu, Kevin Y., et al.
Publicado: (2020)

Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database
por: Saloner, Brendan, et al.
Publicado: (2021)

Longitudinal cognitive development of children born to mothers with opioid and polysubstance use
por: Nygaard, Egil, et al.
Publicado: (2015)

Characterizing the Use of Telepsychiatry for Patients with Opioid Use Disorder and Cooccurring Mental Health Disorders in Ontario, Canada
por: LaBelle, Brittanie, et al.
Publicado: (2018)

Naltrexone Implant for Opioid Use Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021)

Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic
por: Currie, Janet M., et al.
Publicado: (2021)

Health, Polysubstance Use, and Criminal Justice Involvement Among Adults With Varying Levels of Opioid Use
por: Winkelman, Tyler N.A., et al.
Publicado: (2018)

Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder
por: Weintraub, Eric, et al.
Publicado: (2021)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims
por: Xu, Kevin Y, et al.
Publicado: (2023)

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

Association between recent overdose and chronic pain among individuals in treatment for opioid use disorder
por: Hartz, Sarah M., et al.
Publicado: (2022)

Polysubstance use in the U.S. opioid crisis
por: Compton, Wilson M., et al.
Publicado: (2020)

Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl
por: Chambers, Laura C., et al.
Publicado: (2023)

High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
por: Herring, Andrew A., et al.
Publicado: (2021)

Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
por: D’Onofrio, Gail, et al.
Publicado: (2023)

Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
por: Christine, Paul J., et al.
Publicado: (2023)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report
por: Szczesniak, Laura M., et al.
Publicado: (2020)

Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk
por: Tardelli, Vitor, et al.
Publicado: (2023)

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
por: Nguyen, Thuy, et al.
Publicado: (2022)

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
por: Mannelli, Paolo, et al.
Publicado: (2022)

Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic
por: Frost, Madeline C., et al.
Publicado: (2022)

Lower buprenorphine elimination rate constant is associated with lower opioid use
por: Elarabi, Hesham Farouk, et al.
Publicado: (2022)

Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders
por: Clark, Brinton, et al.
Publicado: (2019)

Association Between Workplace Absenteeism and Alcohol Use Disorder From the National Survey on Drug Use and Health, 2015-2019
por: Parsley, Ian C., et al.
Publicado: (2022)

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
por: Comer, Sandra D., et al.
Publicado: (2020)

Associations Between Polysubstance Use Patterns and Receipt of Medications for Opioid Use Disorder Among Adults in Treatment for Opioid Use Disorder
por: Ford, Becky R., et al.
Publicado: (2021)

A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse
por: Bakhti-Suroosh, Anousheh, et al.
Publicado: (2021)

Association of Project ECHO Training With Buprenorphine Prescribing by Primary Care Clinicians in Minnesota for Treating Opioid Use Disorder
por: Solmeyer, Anna R., et al.
Publicado: (2022)

Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs
por: Keshwani, Shailina, et al.
Publicado: (2022)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines
por: Jones, Christopher M., et al.
Publicado: (2023)

Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment
por: Pan, Yue, et al.
Publicado: (2022)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Substance-Specific and Shared Gray Matter Signatures in Alcohol, Opioid, and Polysubstance Use Disorder
por: Muller, Angela M., et al.
Publicado: (2022)

Adoption of Emergency Department–Initiated Buprenorphine for Patients With Opioid Use Disorder: Secondary Analysis of a Cluster Randomized Trial
por: Gao, Evangeline, et al.
Publicado: (2023)

Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia
por: Ruger, Jennifer Prah, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t4s41deb00np7648lrp70vu91j